<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974753</url>
  </required_header>
  <id_info>
    <org_study_id>ERM-JG-2009</org_study_id>
    <nct_id>NCT00974753</nct_id>
  </id_info>
  <brief_title>Prophylactic Ketorolac Post Epiretinal Membrane Surgery</brief_title>
  <official_title>A Placebo-controlled, Randomized, Clinical Trial of Prophylactic Ketorolac 0.5% in Patients Undergoing Pars Plana Vitrectomy and Phacovitrectomy Epiretinal Membrane Peel Surgery: Assessing Macular Volume With Spectral-domain OCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug
      (NSAID), to prevent macular edema after epiretinal membrane surgery. Patients undergoing
      epiretinal membrane surgery have increased risk of macular swelling which can adversely
      affect vision. Since post-intraocular surgery inflammation is a contributing factor to
      macular swelling and loss of vision, NSAID drops may be able to prevent or minimize the
      deleterious effects of macular swelling after epiretinal membrane surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in macular volume from baseline.</measure>
    <time_frame>Before surgery, at 1 week, 1 month, and 1 year after surgery.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>PPV-MP + Placebo (Saline drops)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PPV-MP= pars plana vitrectomy membrane peel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV-MP + Ketorolac 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPV-MP= pars plana vitrectomy membrane peel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PhacoVit-MP + Placebo (Saline drops)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PhacoVit-MP= phacovitrectomy membrane peel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PhacoVit-MP + Ketorolac 0.5%.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PhacoVit-MP= phacovitrectomy membrane peel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac 0.5%</intervention_name>
    <description>Four-times a day starting one week before surgery and continued for 4 weeks post surgery.</description>
    <arm_group_label>PPV-MP + Ketorolac 0.5%</arm_group_label>
    <arm_group_label>PhacoVit-MP + Ketorolac 0.5%.</arm_group_label>
    <other_name>ketorolac tromethamine</other_name>
    <other_name>Apo-Ketorolac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline drops</intervention_name>
    <description>Four-times a day starting one week before surgery and continued for 4 weeks post surgery.</description>
    <arm_group_label>PPV-MP + Placebo (Saline drops)</arm_group_label>
    <arm_group_label>PhacoVit-MP + Placebo (Saline drops)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic epiretinal membrane diagnosis requiring membrane peel surgery

        Exclusion Criteria:

          -  proliferative diabetic retinopathy

          -  sickle cell retinopathy

          -  radiation retinopathy

          -  choroidal folds

          -  hypersensitivity or allergy to NSAIDs

          -  wet macular degeneration

          -  branch retinal vein occlusion (BRVO)

          -  central retinal vein occlusion (CRVO)

          -  complicated membrane peel surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Gale, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Hotel Dieu Hospital, Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epiretinal membrane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

